



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :

A61K 38/45, 48/00, 39/395, C12N 9/12,
15/54, A01K 67/027, C07K 16/40, C12Q
1/48, A61P 25/28

A1

(11) International Publication Number:

WO 00/53218

(43) International Publication Date: 14 September 2000 (14.09.00)

(21) International Application Number: PCT/GB00/00860

(22) International Filing Date: 9 March 2000 (09.03.00)

(30) Priority Data:

9905218.5

9 March 1999 (09.03.99)

GB

(71) Applicant (for all designated States except US): THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow G12 8QQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DAVIES, Roger, Wayne [GB/GB]; University of Glasgow, Institute of Biomedical and Life Sciences, Division of Molecular Genetics, Anderson College, 54 Dumbarton Road, Glasgow G11 6NU (GB). PAYNE, Anthony, Philip [GB/GB]; University of Glasgow, Institute of Biomedical and Life Sciences, West Medical Building, University Avenue, Glasgow G12 8QQ (GB). SUTCLIFFE, Roger, Graham [GB/GB]; University of Glasgow, Institute of Biomedical and Life Sciences, Division of Molecular Genetics, Anderson College, 54 Dumbarton Road, Glasgow G11 6NU (GB).

(74) Agents: McCALLUM, William, Potter et al.; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NEURODEGENERATIVE DISORDER RELATED GENE

(57) Abstract

The present invention relates to the use of a polynucleotide fragment comprising PKC γ gene including type 1 subtype of protein kinase C in the manufacture of a medicament for treating a neurodegenerative disorder. The invention further relates to use of a polypeptide which comprises protein kinase C type 1 in the manufacture of a medicament for treating a neurodegenerative disorder. Further disclosed is a method of testing an animal, such as human, thought to have or be predisposed to having a neurodegenerative disorder which comprises detecting the presence of a mutation in PKC γ gene and/or its associated promoter.